TargED Biopharmaceuticals B.V
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
TargED Biopharmaceuticals B.V - overview
Established
2018
Location
Utrecht, -, Netherlands
Primary Industry
Biotechnology
About
Based in Utrecht, Netherlands, and founded in 2018 by CEO Kristof Vercruysse and co-founders Marc van Moorsel, Steven de Maat, and Coen Maas. TargED Biopharmaceuticals B. V is a biotechnology company that develops biological drugs to improve the treatment of thrombosis. In December 2025, TargED Biopharmaceuticals B.
V raised EUR 21. 5 million in series A funding led by BioGeneration Ventures, with participation from existing investors including Andera Partners, Fund+, Hadean Ventures, Inkef, Sunstone Life Science Ventures and Curie Capital. TargED Biopharmaceuticals B. V develops drugs by using small antibodies to deliver enzymes to sites of thrombosis, enabling targeted thrombolysis.
Its lead product is a Microlyse clot-busting compound that binds to a protein present in all forms of thrombosis. Its mechanism of action allows for potential applications in a variety of indications involving thrombosis, including the life-threatening disease Thrombotic Thrombocytopenic Purpura. The company will use the series A funding to advance clinical programs, start early-stage trials, and develop treatments for thrombotic conditions.
Current Investors
Curie Capital, Fonds InvesteringsRijpe Starters, Utrecht Holdings
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals, Pharmaceuticals
Website
www.targedbiopharmaceuticals.com
Company Stage
Series A
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.